Revlimid.com
- Title
- REVLIMID® (lenalidomide) Treatment for Multiple Myeloma | Mantle Cell Lymphoma | Deletion 5q Myelodysplastic Syndromes
- Meta Description
- About REVLIMID® (lenalidomide) treatment for deletion 5q myelodysplastic syndromes, mantle cell lymphoma and multiple myeloma including full indications, dosing, administration, efficacy, safety & prescribing information. Important Safety Information WARNING: Risk to unborn babies, low blood counts, and blood clots Before you begin taking REVLIMID, you must read and agree to all of the instructions in the REVLIMID REMS® program (formerly known as the RevAssist® program). REVLIMID may cause serious side effects including: Possible birth defects (deformed babies) or death of an unborn baby. Females who are pregnant or who plan to become pregnant must not take REVLIMID. REVLIMID is similar to the medicine thalidomide (THALOMID®). We know thalidomide can cause severe life-threatening birth defects. REVLIMID has not been tested in pregnant females. REVLIMID has harmed unborn animals in animal testing. In females of childbearing potential, obtain 2 negative pregnancy tests before ...
- Meta Keywords
- REVLIMID, lenalidomide, Treatment, deletion 5q myelodysplastic syndromes, mantle cell lymphoma, Multiple Myeloma, newly diagnosed, indications, dosing, administration, efficacy, prescribing information, mechanism of action, trial design, dosing schedule, dosing modification, celgene